Evidence map›Paper›PMID 34298692›Full record

ArticleCancers2021

Differential but Concerted Expression of HSD17B2, HSD17B3, SHBG and SRD5A1 Testosterone Tetrad Modulate Therapy Response and Susceptibility to Disease Relapse in Patients with Prostate Cancer.

Oluwaseun Adebayo Bamodu, Kai-Yi Tzou, Chia-Da Lin, Su-Wei Hu, Yuan-Hung Wang, Wen-Ling Wu, Kuan-Chou Chen, Chia-Chang Wu

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Oluwaseun Adebayo BamoduDepartment of Urology, Taipei Medical University-Shuang Ho Hospital, New Taipei City 23561, Taiwan.ORCID 0000-0001-8229-0408
Kai-Yi TzouDepartment of Urology, Taipei Medical University-Shuang Ho Hospital, New Taipei City 23561, Taiwan.
Chia-Da LinDepartment of Urology, Taipei Medical University-Shuang Ho Hospital, New Taipei City 23561, Taiwan.
Su-Wei HuDepartment of Urology, Taipei Medical University-Shuang Ho Hospital, New Taipei City 23561, Taiwan.
Yuan-Hung WangDepartment of Medical Research and Education, Taipei Medical University-Shuang Ho Hospital, New Taipei City 23561, Taiwan.
Wen-Ling WuDepartment of Urology, Taipei Medical University-Shuang Ho Hospital, New Taipei City 23561, Taiwan.
Kuan-Chou ChenDepartment of Urology, Taipei Medical University-Shuang Ho Hospital, New Taipei City 23561, Taiwan.
Chia-Chang WuDepartment of Urology, Taipei Medical University-Shuang Ho Hospital, New Taipei City 23561, Taiwan.
Taipei Medical University-Shuang Ho Hospital · TW

Funding

Teh-Tzer Study Group for Human Medical Research Foundation (TMRF) A1091044
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

advanced diseaseandrogenic reprogrammingcastration-resistanceHSD17B2HSD17B3prostate cancerSHBG and SRD5A1testosterone metabolismtherapy resistance

Identifiers

PMID34298692
PMCPMC8303483
OpenAlexW3182832793

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.